Piramal sells its cartilage repair product

January 14, 2016 | Thursday | News | By BioSpectrum Bureau

Piramal sells its cartilage repair product

$BST-CarGel is a first-line cartilage repair product used along with microfracture and other bone marrow$

BST-CarGel is a first-line cartilage repair product used along with microfracture and other bone marrow

Piramal Enterprises announces the sale of BST-CarGel from Piramal Healthcare (Canada) Limited, based in Montreal, Canada to Smith and Nephew, the global medical technology business.

BST-CarGel is a first-line cartilage repair product used along with microfracture and other bone marrow stimulation techniques for the initial treatment of most sizes of focal cartilage tears.

Through this transaction, an affiliate of Smith and Nephew will acquire ownership of all product and intellectual property assets related to BST-CarGel.

The transaction does not have a material impact on the financials of Piramal.